human t-cell lymphotropic virus type iii (htlv-iii) embryopathy. a new dysmorphic syndrome associated with intrauterine htlv-iii infection.

NLM AIDSLINE Human T-cell lymphotropic virus type III (HTLV-III) embryopathy. A new dysmorphic syndrome associated with intrauterine HTLV-III infection. Marion RW; Wiznia AA; Hutcheon G; Rubinstein A
September 30, 1986

Am J Dis Child. 1986 Jul;140(7):638-40. Unique Identifier : AIDSLINE Twenty infants and children with positive serologic tests for the human T-cell lymphotropic virus type III (HTLV-III) were noted to have similar features including growth failure (75%), microcephaly (70%), and craniofacial abnormalities consisting of ocular hypertelorism (50%); prominent box-like appearance of the forehead (75%); flat nasal bridge (70%); mild upward or downward obliquity of the eyes (65%); long palpebral fissures with blue sclerae (60%); short nose with flattened columella and well-formed, triangular philtrum (65%); and patulous lips (60%). These features constitute a new and distinct dysmorphic syndrome, the HTLV-III embryopathy. Acquired Immunodeficiency Syndrome/CONGENITAL/COMPLICATIONS Anthropometry Antibodies, Viral/ANALYSIS Child, Preschool Facial Bones/ABNORMALITIES Female Fetal Diseases/MICROBIOLOGY Fetal Growth Retardation/ETIOLOGY Growth Disorders/ETIOLOGY Human HTLV-BLV Viruses/IMMUNOLOGY Infant Male Pregnancy Retroviridae Infections/MICROBIOLOGY Skull/ABNORMALITIES Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 CANADA: Health Officials in St. John's N.L., Inform 50 People of Tuberculosis Risk OHIO: Cleveland LGBT Community Center Offers Free Support Groups and HIV, STD Testing: The Frugal Patient CALIFORNIA: Local Church Sends HIV/AIDS Care Packs to Swaziland NEVADA: Clinics Offer Low-Cost Care for those Lacking Insurance CONNECTICUT: At Hartford Public High School, A Day Reserved for 'Healthy Relationships' ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment KENYA: Kenya Launches Universal HPV Vaccine Access to Youths UNITED STATES: Navajo Confront an Increase in New H.I.V. Infections Uganda: HIV Vaccine Trials to Start in July Uganda: Remembering Those Killed By HIV/AIDS (International AIDS Candlelight Memorial) UNITED STATES: Navajo Confront an Increase in New H.I.V. Infections Navajo Confront an Increase in New H.I.V. Infections Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics® For Monogenic Diseases NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing 1 new hepatitis case in Okla. public health scare NEW JERSEY: Drug Company Donates Thousands to HIV/AIDS Orgs PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents UNITED STATES: New AIDS Group Debuts as NAPWA Successor Toronto Public Health urges vaccination against bacterial meningitis for MSM travelling to New York Researchers from Albert Einstein College of Medicine Report Details of New Studies and Findings in the Area of HIV/AIDS
Information in this article was accurate in September 30, 1986. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.